CARY, NC — February 1, 2016 — Biologics, Inc. has been selected by TESARO, Inc. as the exclusive specialty pharmacy provider for VARUBI™ (rolapitant), the company is pleased to announce. VARUBI was approved by the U.S. Food and Drug Administration on September 1, 2015, in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.
“TESARO is very pleased to be working with Biologics as the exclusive Specialty Pharmacy provider for VARUBI. We selected Biologics because it focuses exclusively in the area of oncology and has excellent relationships with clinical practices,” said Grant Bogle, Senior Vice President and Chief Commercial Officer of TESARO. “Biologics will support TESARO’s business model by offering an access point to serve patients who are not able to receive VARUBI at an in-office dispensing oncology practice, hospital or cancer center.”
Physicians may submit prescriptions to Biologics via phone (800.850.4306, option 2), fax (800.823.4506) or eScribe. For electronic prescribing systems, physicians may search for Biologics within their EMR system.
- Pharmacy name: Biologics
- Street address: 13000 Weston Parkway, Suite 105, Cary, NC 27513
- NCPDP: 3430369
- NPI: 1487640314
Biologics takes a high-touch approach to patient care, providing a dedicated pharmacist and nurse to each individual patient in order to support their clinical, financial and emotional needs.
Individualized care plans are created for each patient, and the Biologics team works with the patient to manage side effects, adhere to therapy and answer any questions the patient has about their disease.
In an independent survey, 96% of patients reported they had an exceptional overall experience with Biologics.
About VARUBI™
VARUBI is a substance P/neurokinin-1 (NK-1) receptor antagonist indicated in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. VARUBI is contraindicated in patients receiving thioridazine, a CYP2D6 substrate. The inhibitory effect of a single dose of VARUBI on CYP2D6 lasts at least seven days and may last longer. Avoid use of pimozide; monitor for adverse events if concomitant use with other CYP2D6 substrates with a narrow therapeutic index cannot be avoided. Please see full prescribing information, including additional important safety information, available at www.varubirx.com.
About Biologics
Biologics, Inc. is an oncology pharmacy services company that empowers healthcare providers, payers and biopharma to optimize cancer care for the best possible outcomes – clinical, financial and emotional. Unifying fragmented healthcare services, Biologics brings efficiency and humanity to oncology care management by focusing on the patient’s best interest as the surest path to managing cost and risk.
Biologics is part of McKesson Life Sciences (formerly McKesson Specialty Health), a division of McKesson Corporation empowering the community patient care delivery system by helping community practices advance the science, technology and quality of care. Through innovative clinical research, business and operational solutions, facilitated by integrated technology systems, we focus on improving the financial health of our customers so they may provide the best care to their patients. Our combined organization will help better support patients and expedite access to oncology therapies. For more information, visit www.mckessonspecialtyhealth.com and www.biologicsinc.com.
Media Contact
McKesson
Claire Crye
281.825.9927
claire.crye@mckesson.com